Shire wins DermaGraft nod in Canada
Health Canada approves the DermaGraft regenerative skin patch for patients with diabetic foot ulcers.
Regulators north of the border gave Shire  (NSDQ:SHPGY ) its first approval outside of the U.S. for the DermaGraft regenerative skin patch it bought when it acquired Advanced BioHealing last year.
The British biotech giant said Health Canada approved DermaGraft as a Class IV medical device for diabetic foot ulcers, noting in a press release that the approval is "an important first step for the company as it continues to develop its international expansion strategy."
A launch in Canada is slated for the 1st quarter of 2013, according to the release .